TLC to Present at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan - September 9, 2021 - TLC (Nasdaq: TLC, TWO: 4152), a clinical-stagespecialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company's management team will be presenting at the following virtual investor conferences:

HC Wainwright & Co 23rd Annual Global Investment Conference

September 13-15, 2021

Presentation will be available on-demand during the conference

2021 Cantor Virtual Global Healthcare Conference

September 27-30, 2021

Presentation: 10:00am ET, Monday, September 27, 2021

The management team will also be participating in one-on-one meetings during the conference. The corporate presentation will be available on the TLC website at www.tlcbio.com in the Investors section, under News & Events.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC's deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLC's BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology has been proven in two approved drugs and is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, infectious diseases, ophthalmology, and oncology.

Contact

Dawn Chi

Corporate Communications dawn@tlcbio.com

Attachments

Disclaimer

Taiwan Liposome Co. Ltd. published this content on 09 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2021 04:21:01 UTC.